Abstract
Immune privilege provides protection to vital tissues or cells of the body when foreign antigens are introduced into these sites. The modern concept of relative immune privilege applies to a variety of tissues and anatomical structures, including the hair follicles and mucosal surfaces. Even sites of chronic inflammation and developing tumors may acquire immune privilege by recruiting immunoregulatory effector cells. Adult stem cells are no exception. For their importance and vitality, many adult stem cell populations are believed to be immune privileged. A preimplantation-stage embryo that derives from a totipotent stem cell (i.e., a fertilized oocyte) must be protected from maternal allo-rejection for successful implantation and development to occur. Embryonic stem cells, laboratory-derived cell lines of preimplantation blastocyst-origin, may, therefore, retain some of the immunological properties of the developing embryo. However, embryonic stem cells and their differentiated tissue derivatives transplanted into a recipient do not necessarily have an ability to subvert immune responses to the extent required to exploit their pluripotency for regenerative medicine. In this review, an extended definition of immune privilege is developed and the capacity of adult and embryonic stem cells to display both relative and acquired immune privilege is discussed. Furthermore, we explore how these intrinsic properties of stem cells may one day be harnessed for therapeutic gain.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- APC:
-
Antigen-presenting cell
- CCR4:
-
CC chemokine receptor 4
- DC:
-
Dendritic cell
- ES:
-
Embryonic stem
- HSC:
-
Hematopoietic stem cell
- IDO:
-
Indoleamine 2,3 dioxygenase
- IFN:
-
Interferon
- IL-10:
-
Interleukin-10
- IVD:
-
Intervertebral disk
- KIR:
-
Killer cell immunoglobulin-like receptor
- mCRPs:
-
Membrane complement regulatory proteins
- MHC:
-
Major histocompatibility complex
- MICA:
-
MHC class I chain-related gene A
- MIF:
-
Migration inhibitory factor
- MSC:
-
Mesenchymal stem cell
- NK:
-
Natural killer cell
- NSC:
-
Neural stem cell
- TGF-β:
-
Transforming growth factor β
- Treg:
-
Regulatory T cell
- uNK:
-
Uterine natural killer cell
References
Wahl SM, Wen J, Moutsopoulos N (2006) TGF-β: a mobile purveyor of immune privilege. Immunol Rev 213:213–227
Simpson E (2006) A historical perspective on immunological privilege. Immunol Rev 213: 12–22
Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3:879–889
Niederkorn JY (2006) See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 7:354–359
Paus R, Nickoloff BJ, Ito T (2005) A “hairy” privilege. Trends Immunol 26:32–40
Mellor AL, Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8:74–80
Cobbold SP, Adams E, Graca L et al (2006) Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 213:239–255
Chuang JC, Yu CL, Wang SR (1990) Modulation of human lymphocyte proliferation by amino acids. Clin Exp Immunol 81:173–176
Calder PC (2006) Branched-chain aminoacids and immunity. J Nutr 136:288S–293S
Munn DH, Zhou M, Attwood JT et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191–1193
Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:641–654
Cobbold SP, Adams E, Farquhar CA et al (2009) Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci 106:12055–12060
Moffett A, Loke C (2006) Immunology of placentation in eutherian mammals. Nat Rev Immunol 6:584–594
Riley JK, Yokoyama WM (2008) NK cell tolerance and the maternal-fetal interface. Am J Reprod Immunol 59:371–387
Hunt JS, Petroff MG, McIntire RH et al (2005) HLA-G and immune tolerance in pregnancy. FASEB J 19:681–693
Ito T, Ito N, Saatoff M et al (2008) Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 128:1196–1206
Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
Hori J, Wang M, Miyashita M et al (2006) B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 177:5928–5935
Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800
Askenasy N, Yolcu ES, Yaniv I et al (2005) Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105:1396–1404
Fishelson Z, Donin N, Zell S et al (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123
Halme J, Sachse M, Vogel H et al (2009) Primary human hepatocytes are protected against complement by multiple regulators. Mol Immunol 46:2284–2289
Tat FN, Lavik E, Keino H et al (2007) Creating an immune-privileged site using retinal progenitor cells and biodegradable polymers. Stem Cells 25:1552–1559
Arck PC, Gilhar A, Bienenstock J et al (2008) The alchemy of immune privilege explored from a neuroimmunological perspective. Curr Opin Pharm 8:480–489
Somerset DA, Zheng Y, Kilby MD et al (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD25+CD4+ regulatory T-cell subset. Immunology 112:38–43
Aluvihare VR, Kallikourdis M, Betz AG (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5:266–271
Ishida T, Ishii T, Inagaki A et al (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66:5716–5722
Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
Muller AJ, Sharma MD, Chandler PR et al (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 105: 17073–17078
Liu Y, Elf SE, Miyata Y et al (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4:37–48
Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6:93–106
Fändrich F, Dresske B, Bader M et al (2002) Embryonic stem cells share immune-privileged features relevant for tolerance induction. J Mol Med 80:343–350
Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726–736
Jones S, Horwood N, Cope A et al (2007) The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179:2824–2831
Ramasamy R, Lam EWF, Soeiro I et al (2007) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21:304–310
Sheng H, Wang Y, Jin Y et al (2008) A critical role of IFN? in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 18:846–857
Francesco Dazzi Federica MM-B (2008) Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur J Immunol 38:1479–1482
Hiyama A, Mochida J, Iwashina T et al (2008) Transplantation of mesenchymal stem cells in a canine disc degeneration model. J Orth Res 26:589–600
Hori J, Ng TF, Shatos M et al (2007) Neural progenitor cells lack immunogenicity and resist destruction as allografts. Ocul Immunol Inflamm 15:261–273
Grinnemo KH, Kumagai-Braesch M, MaÌŠnsson-Broberg A et al (2006) Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod BioMed Online 13:712–724
Li L, Baroja ML, Majumdar A et al (2004) Human embryonic stem cells possess immune-privileged properties. Stem Cells 22:448–456
Koch CA, Geraldes P, Platt JL (2008) Immunosuppression by embryonic stem cells. Stem Cells 26:89–98
Chidgey AP, Boyd RL (2008) Immune privilege for stem cells: not as simple as it looked. Cell Stem Cell 3:357–358
Swijnenburg R-J, Schrepfer S, Govaert JA et al (2008) Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci 105:12991–12996
Dai W, Field LJ, Rubart M et al (2007) Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J Mol Cell Cardiol 43:504–516
Fairchild PJ, Cartland S, Nolan KF et al (2004) Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol 25:465–470
Puymirat E, Geha R, Tomescot A et al (2008) Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells? Mol Ther 17:176–182
Robertson NJ, Brook FA, Gardner RL et al (2007) Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 104:20920–20925
Wu DC, Boyd AS, Wood KJ (2008) Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 26:1939–1950
Lui KO, Waldmann H, Fairchild PJ (2009) Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy. Curr Stem Cell Res Ther 4:70–80
Drukker M (2006) Immunogenicity of embryonic stem cells and their progeny. In: Lanza R, Klimanskaya I (eds) Methods enzymol. Academic, San Diego, CA
Lubin I, Segall H, Marcus H et al (1994) Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83:2368–2381
Fändrich F, Lin X, Chai GX et al (2002) Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 8:171–178
Magliocca JF, Held IKA, Odorico JS (2006) Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev 15:707–717
Bonde S, Chan KM, Zavazava N (2008) ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS One 3:e3212
Acknowledgments
We are grateful to Dr Stephen Cobbold for helpful discussions. Work on immune privilege in the authors’ laboratory is supported by seed funding from the Oxford Stem Cell Institute and by grant G0802538 from the Medical Research Council (UK).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ichiryu, N., Fairchild, P.J. (2013). Immune Privilege of Stem Cells. In: Zavazava, N. (eds) Embryonic Stem Cell Immunobiology. Methods in Molecular Biology, vol 1029. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-478-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-478-4_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-477-7
Online ISBN: 978-1-62703-478-4
eBook Packages: Springer Protocols